Allogeneic Segment Held Largest Share of Europe Cell therapy Market in 2019
According to our new market research study on “Europe Cell therapy Market to 2027 - Regional Analysis and Forecast - by therapy type, product, technology, application, end user,” the market is expected to reach US$ 3,610.7 million by 2027 from US$ 2,125.7 million in 2019; it is anticipated to grow at a CAGR of 6.9% during 2019-2027. The report provides trends prevailing in the Europe cell therapy market, and drivers and restraints pertaining to the market growth.
The Europe cell therapy market based on therapy type is segmented into allogeneic, and autologous. In 2019, the allogeneic segment accounted for the highest share owing to the availability of substantial number of approved products for clinical use. For instance, in 2018, Alofisel developed by TiGenix (Takeda) is the first allogeneic stem cell-based therapy approved for use in Europe. However, the autologous segment is likely register the highest CAGR in the market during the forecast period.
The growth of the Europe cell therapy market is mainly attributed to increasing prevalence of chronic diseases, rising adoption of regenerative medicines, and increasing number of approvals for cell-based therapies. However, high cost of cell therapy manufacturing is the major factor hindering the market growth in Europe.
A few of the leading companies operating in the Europe cell therapy market are Vericel Corporation, MEDIPOST, NuVasive, Inc., Mesoblast Limited, Smith & Nephew, Bristol-Myers Squibb Company, Cells for Cells, Stemedica Cell Technologies, Inc.. and others.
The report segments Europe cell therapy market as follows:
Europe Cell therapy Market - By Therapy Type
Europe Cell therapy Market - By Product
Europe Cell therapy Market - By Technology
Europe Cell therapy Market - By Application
Europe Cell therapy Market - By End User
Europe Cell therapy Market - By Country
Reasons to Buy
It provides understanding of the Europe, Cell therapy market landscape and identifies Cell therapy market segments that are most likely to guarantee a strong return.It guides
Stay ahead of the race by comprehending the ever-changing competitive landscape for the Europe Cell therapy market.It helps
Efficiently plan merger and acquisition, and partnership deals in the Cell therapy market by identifying market segments with the most promising probable sales.
It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of Cell therapy market performance of various segments pertaining to the Europe Cell therapy market.
It provides Cell therapy market revenue forecast of the market based on various segments for the period from 2019 to 2027.
According to our new market research study on “Europe Cell therapy Market to 2027 - Regional Analysis and Forecast - by therapy type, product, technology, application, end user,” the market is expected to reach US$ 3,610.7 million by 2027 from US$ 2,125.7 million in 2019; it is anticipated to grow at a CAGR of 6.9% during 2019-2027. The report provides trends prevailing in the Europe cell therapy market, and drivers and restraints pertaining to the market growth.
The Europe cell therapy market based on therapy type is segmented into allogeneic, and autologous. In 2019, the allogeneic segment accounted for the highest share owing to the availability of substantial number of approved products for clinical use. For instance, in 2018, Alofisel developed by TiGenix (Takeda) is the first allogeneic stem cell-based therapy approved for use in Europe. However, the autologous segment is likely register the highest CAGR in the market during the forecast period.
The growth of the Europe cell therapy market is mainly attributed to increasing prevalence of chronic diseases, rising adoption of regenerative medicines, and increasing number of approvals for cell-based therapies. However, high cost of cell therapy manufacturing is the major factor hindering the market growth in Europe.
A few of the leading companies operating in the Europe cell therapy market are Vericel Corporation, MEDIPOST, NuVasive, Inc., Mesoblast Limited, Smith & Nephew, Bristol-Myers Squibb Company, Cells for Cells, Stemedica Cell Technologies, Inc.. and others.
The report segments Europe cell therapy market as follows:
Europe Cell therapy Market - By Therapy Type
- Allogeneic
- Autologous
Europe Cell therapy Market - By Product
- Consumables
- Equipment
- Systems and Software
Europe Cell therapy Market - By Technology
- Viral Vector Technology
- Genome Editing Technology
- Somatic Cell Technology
- Cell Immortalization Technology
- Cell Plasticity Technology
- Three-Dimensional Technology
Europe Cell therapy Market - By Application
- Oncology
- Cardiovascular
- Orthopedic
- Wound Management
- Other Applications
Europe Cell therapy Market - By End User
- Research Institutes
- Hospitals
- Others
Europe Cell therapy Market - By Country
- Europe
- Germany
- France
- Italy
- UK
- Spain
Reasons to Buy
It provides understanding of the Europe, Cell therapy market landscape and identifies Cell therapy market segments that are most likely to guarantee a strong return.It guides
Stay ahead of the race by comprehending the ever-changing competitive landscape for the Europe Cell therapy market.It helps
Efficiently plan merger and acquisition, and partnership deals in the Cell therapy market by identifying market segments with the most promising probable sales.
It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of Cell therapy market performance of various segments pertaining to the Europe Cell therapy market.
It provides Cell therapy market revenue forecast of the market based on various segments for the period from 2019 to 2027.
Table of Contents
1. Introduction
3. Research Methodology
4. Europe Cell therapy- Market Landscape
5. Europe Cell Therapy Market - Key Industry Dynamics
6. Cell therapy Market - Europe Analysis
7. Cell therapy Market Analysis - By Therapy Type
8. Cell therapy Market Analysis - By Product
9. Cell therapy Market Analysis - By Technology
10. Cell therapy Market Analysis - By Application
11. Cell therapy Market Analysis - By End User
12. Cell therapy Market - Geographic Analysis
13. Impact of COVID-19 Pandemic on Europe Cell Therapy Market
14. Cell Therapy Market- Industry Landscape
15. Company Profiles
16. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Vericel Corporation
- MEDIPOST
- NuVasive, Inc.
- Mesoblast Limited
- Smith & Nephew
- Bristol-Myers Squibb Company
- Cells for Cells
- Stemedica Cell Technologies, Inc.
